p53 as a target for anti-cancer drug development.

Loss of p53 function compromises genetic homeostasis in cells exhibiting deregulated DNA replication and/or DNA damage, and prevents normal cytotoxic responses to cancer therapies. Genetic and pharmacological approaches are being developed with the ultimate goal of restoring or controlling p53 functions in cancer patients. Progress has recently been made in the clinical use of replication-deficient virus carrying wt-TP53 (Ad5CMV-p53) and/or cancer-selective oncolytic adenoviruses (ONYX-015). These strategies demonstrated clinical activity as monotherapy and were synergistic with traditional chemotherapy agents in the treatment of some types of cancer. In addition, pharmacological methods are under development to either stimulate wild-type p53 protein function, or induce p53 mutant proteins to resume wild-type functions. These methods are based on small chemicals (CP-31388, PRIMA-1), peptides (CDB3) or single-chain Fv antibody fragments corresponding to defined p53 domains. Here, we discuss the mechanisms underlying these approaches and their perspectives for cancer therapy.

[1]  K. Vousden,et al.  Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function , 1996, Molecular and cellular biology.

[2]  C. Harris,et al.  The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.

[3]  R. Salvi,et al.  Pifithrin-α supresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis , 2003, Neuroscience.

[4]  D. Kramer,et al.  Polyamine analogue induction of the p53-p21WAF1/CIP1-Rb pathway and G1 arrest in human melanoma cells. , 1999, Cancer research.

[5]  Y. Nakamura,et al.  The role of p53-target genes in human cancer. , 2000, Critical reviews in oncology/hematology.

[6]  D. Nettelbeck,et al.  Transcriptional targeting for ovarian cancer gene therapy. , 2001, Gynecologic oncology.

[7]  V. Hervieu,et al.  Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics , 2003, British Journal of Cancer.

[8]  A. Balmain,et al.  Replication of an E1B 55-Kilodalton Protein-Deficient Adenovirus (ONYX-015) Is Restored by Gain-of-Function Rather than Loss-of-Function p53 Mutants , 2003, Journal of Virology.

[9]  J. Sloan,et al.  Phase I–II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas , 2005, Gene Therapy.

[10]  M. Vidal,et al.  Dominant-negative p53 mutations selected in yeast hit cancer hot spots. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Gulley,et al.  A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  R. Herrmann,et al.  Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Nemunaitis,et al.  Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients , 2003, Cancer Gene Therapy.

[14]  Sheng-tian Li,et al.  Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells. , 2002, Molecular cancer therapeutics.

[15]  B. Gusterson,et al.  Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions , 1999, Oncogene.

[16]  D. Kirn,et al.  ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents , 1997, Nature Medicine.

[17]  K. Roemer,et al.  Inhibition of p53 protects liver tissue against endotoxin‐induced apoptotic and necrotic cell death , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  B. Foster,et al.  Pharmacological rescue of mutant p53 conformation and function. , 1999, Science.

[19]  A. Balmain,et al.  Replication of an E 1 B 55-Kilodalton Protein-Deficient Adenovirus ( ONYX-015 ) Is Restored by Gain-of-Function Rather than Loss-of-Function p 53 Mutants , 2003 .

[20]  H. Matsubara,et al.  Combinatory anti-tumor effects of electroporation-mediated chemotherapy and wild-type p53 gene transfer to human esophageal cancer cells. , 2001, International journal of oncology.

[21]  H. Bruch,et al.  Acceleration of Cutaneous Wound Healing by Transient p53 Inhibition , 2002, Laboratory Investigation.

[22]  A. Venook,et al.  Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial , 2001, Gene Therapy.

[23]  M V Chernov,et al.  A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. , 1999, Science.

[24]  R. Marciniak,et al.  Targeted gene therapy for breast cancer with truncated Bid , 2006, Cancer Gene Therapy.

[25]  F. Khuri,et al.  Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[27]  A. El‐Naggar,et al.  Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity , 2000, Cancer Gene Therapy.

[28]  G. Zambetti,et al.  The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. , 2001, Gene.

[29]  M. Gore,et al.  Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  B. Hann,et al.  Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015) , 2000, Nature Medicine.

[31]  A. Fattaey,et al.  An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.

[32]  P. Komarov,et al.  p53 Inhibitor Pifithrin α Can Suppress Heat Shock and Glucocorticoid Signaling Pathways* , 2003, The Journal of Biological Chemistry.

[33]  M. Schuler,et al.  Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  B. Karlan,et al.  Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500 , 2002, Cancer Gene Therapy.

[35]  Galina Selivanova,et al.  Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. , 2002, Carcinogenesis.

[36]  B. Weintraub,et al.  Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. , 1995, Human gene therapy.

[37]  J. Royds,et al.  Evidence that Replication of the Antitumor Adenovirus ONYX-015 Is Not Controlled by the p53 and p14ARF Tumor Suppressor Genes , 2002, Journal of Virology.

[38]  D. Gridley,et al.  Evaluation of radiation effects against C6 glioma in combination with vaccinia virus-p53 gene therapy. , 1998, International journal of oncology.

[39]  R. Klinke,et al.  A Chemical Inhibitor of p 53 That Protects Mice from the Side Effects of Cancer Therapy , 1999 .

[40]  J. Hecht,et al.  Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  P. Branton,et al.  Adenovirus E1A proteins induce apoptosis by both p53-dependent and p53-independent mechanisms. , 1995, Oncogene.

[42]  L. Bracco,et al.  Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments , 1999, Oncogene.

[43]  J. Nemunaitis,et al.  Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity , 2001, Gene Therapy.

[44]  J. Bergh,et al.  Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors , 2000, Cancer Gene Therapy.

[45]  J. Hecht,et al.  A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  D. Sze,et al.  Dr. Gary J. Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival. , 2003, Journal of vascular and interventional radiology : JVIR.

[47]  R. Iggo,et al.  Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast , 1998, Oncogene.

[48]  Susan M. Chang,et al.  Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  R. Chanock,et al.  Infections in 18,000 infants and children in a controlled study of respiratory tract disease. I. Adenovirus pathogenicity in relation to serologic type and illness syndrome. , 1969, American journal of epidemiology.

[50]  F. Khuri,et al.  Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. , 2000, Cancer research.

[51]  G. S. Johnson,et al.  An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.

[52]  P. Hainaut,et al.  TP53 and mutations in human cancer. , 2003, Acta biochimica Polonica.

[53]  D. Sze,et al.  Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial , 2001, Gene Therapy.

[54]  J. Roth,et al.  Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. , 1993, Human gene therapy.

[55]  J. Gu,et al.  Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  M. Capogrossi,et al.  Adenovirus-mediated wild-type p53 overexpression reverts tumourigenicity of human mesothelioma cells. , 2000, International journal of molecular medicine.

[57]  S. Lippman,et al.  Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  A. Shiau,et al.  Hepatitis B virus X protein sensitizes hepatocellular carcinoma cells to cytolysis induced by E1B-deleted adenovirus through the disruption of p53 function. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[59]  S. Kügler,et al.  Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand. , 2001, Cancer research.

[60]  R. Kreienberg,et al.  Adenoviral Transduction Efficiency of Ovarian Cancer Cells Can Be Limited by Loss of Integrin β3 Subunit Expression and Increased by Reconstitution of Integrin αvβ3 , 2001 .

[61]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[62]  R. Kreienberg,et al.  Retrovirally mediated wild‐type p53 restores S‐phase modulation without inducing WAF1 mRNA in breast carcinoma cells containing mutant p53 , 1995, Journal of cellular biochemistry.

[63]  R. Kreienberg,et al.  Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin beta3 subunit expression and increased by reconstitution of integrin alphavbeta3. , 2001, Human gene therapy.

[64]  S. Wadler,et al.  Persistent replication of the modified chimeric adenovirus ONYX-015 in both tumor and stromal cells from a patient with gall bladder carcinoma implants. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[65]  T. Nukiwa,et al.  Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene. , 2000, Cancer letters.

[66]  A. Puisieux,et al.  Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity , 2001, British Journal of Cancer.

[67]  C. Rudin,et al.  An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  S. Hirschfeld,et al.  Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  F. McCormick,et al.  Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. , 2005, Cancer cell.

[70]  K. Wiman,et al.  Small molecules that reactivate mutant p53. , 2003, European journal of cancer.

[71]  Galina Selivanova,et al.  Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound , 2002, Nature Medicine.

[72]  Tong-Yuan Yang,et al.  Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer , 2003, Cancer Gene Therapy.

[73]  F. Lacroix,et al.  Cancer gene therapy mediated by CTS1, a p53 derivative: Advantage over wild-type p53 in growth inhibition of human tumors overexpressing MDM2 , 2000, Cancer Gene Therapy.

[74]  J. Roth,et al.  Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis. , 1993, BioTechniques.

[75]  Hepeng Jia,et al.  China approves first gene therapy , 2004, Nature Biotechnology.

[76]  J. Gaydos,et al.  Simultaneous administration of live, enteric-coated adenovirus types 4, 7 and 21 vaccines: safety and immunogenicity. , 1979, The Journal of infectious diseases.

[77]  David P. Lane,et al.  Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo , 1997, Current Biology.

[78]  A. Fusco,et al.  ONYX-015 enhances radiation-induced death of human anaplastic thyroid carcinoma cells. , 2003, The Journal of clinical endocrinology and metabolism.

[79]  Weiya Ma,et al.  Pifithrin‐α promotes p53‐mediated apoptosis in JB6 cells , 2003 .

[80]  P. Hainaut,et al.  Genotoxic and non-genotoxic pathways of p53 induction. , 2001, Cancer letters.

[81]  C. Marth,et al.  Why did p53 gene therapy fail in ovarian cancer? , 2003, The Lancet. Oncology.

[82]  J. Eastham,et al.  Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer. , 2000, The Journal of urology.

[83]  B. Karlan,et al.  A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer , 2002, Cancer Gene Therapy.

[84]  F. Graham,et al.  Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer. , 1998, Human gene therapy.

[85]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[86]  R. Salvi,et al.  Pifithrin-alpha suppresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis. , 2003, Neuroscience.

[87]  P. Opolon,et al.  Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts , 2003, British Journal of Cancer.

[88]  T. Ørntoft,et al.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis , 2005, Nature.

[89]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[90]  E. Chang,et al.  Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. , 2002, Molecular cancer therapeutics.

[91]  W. Hong,et al.  Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer. , 1996, Nature Medicine.

[92]  T. Patel,et al.  Polyamine depletion arrests cell cycle and induces inhibitors p21(Waf1/Cip1), p27(Kip1), and p53 in IEC-6 cells. , 1999, The American journal of physiology.

[93]  Bing Chen,et al.  Radiation Enhances the Anti-tumor Effects of Vaccinia-p53 Gene Therapy in Glioma , 2003, Technology in cancer research & treatment.

[94]  L. Bracco,et al.  CTS1: a p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties. , 1998, The Journal of clinical investigation.

[95]  C. Harris,et al.  Radical causes of cancer , 2003, Nature Reviews Cancer.

[96]  S. Wadler,et al.  Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[97]  J. Bos,et al.  Infectivity and expression of the early adenovirus proteins are important regulators of wild-type and ΔE1B adenovirus replication in human cells , 1999, Oncogene.

[98]  I. Tannock,et al.  A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.

[99]  J. Roth,et al.  A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. , 1993, Cancer research.

[100]  G. Cohen,et al.  Single-chain antibody against the common epitope of mutant p53: isolation and intracytosolic expression in mammalian cells. , 2001, Journal of immunological methods.

[101]  J. Roth,et al.  Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection. , 2000, Chest.

[102]  Dimitris Kletsas,et al.  Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions , 2005, Nature.

[103]  D. Kramer,et al.  Polyamine Analogue Induction of the p 53-p 21 WAF 1 / CIP 1-Rb Pathway and G 1 Arrest in Human Melanoma Cells 1 , 1999 .

[104]  S. Kato,et al.  Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[105]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[106]  H. Miyake,et al.  Synergistic chemosensitization and inhibition of tumor growth and metastasis by adenovirus-mediated P53 gene transfer in human bladder cancer model. , 2000, Urology.

[107]  F. Khuri,et al.  Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. , 1999, Journal of the National Cancer Institute.

[108]  A. Puisieux,et al.  Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. , 2004, Cancer cell.

[109]  Arnold J. Levine,et al.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.

[110]  D. Curiel,et al.  Infectivity enhanced, hTERT promoter-based conditionally replicative adenoviruses are useful for SCLC treatment , 2005, Cancer Gene Therapy.

[111]  Anthony R. Hall,et al.  p53-dependent cell death/apoptosis is required for a productive adenovirus infection , 1998, Nature Medicine.

[112]  D. Bodurka,et al.  A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. , 2004, Gynecologic oncology.

[113]  E. Chang,et al.  Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti-Transferrin Receptor scFv , 2001, Molecular medicine.

[114]  R. Herrmann,et al.  A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. , 1998, Human gene therapy.

[115]  M. Widschwendter,et al.  Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas , 2002, Gene Therapy.

[116]  L. Greco,et al.  Preliminary report: the short-term effects of direct p53 DNA injection in primary hepatocellular carcinomas. , 1996, Cancer detection and prevention.

[117]  C. White,et al.  Polyamine analogue-mediated cell cycle responses in human melanoma cells involves the p53, p21, Rb regulatory pathway. , 1998, Biochemical Society transactions.

[118]  A. Shiau,et al.  Hepatitis B Virus X Protein Sensitizes Hepatocellular Carcinoma Cells to Cytolysis Induced by E 1 B-deleted Adenovirus through the Disruption of p 53 Function 1 , 2003 .

[119]  J. Minna,et al.  Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[120]  M. Oren,et al.  Decision making by p53: life, death and cancer , 2003, Cell Death and Differentiation.

[121]  M. Schuler,et al.  Successful Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients With Bladder Cancer by Intravesical Vector Instillation , 2002 .

[122]  Bing Chen,et al.  Evaluation of combined vaccinia virus–mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model , 2000, Cancer Gene Therapy.

[123]  L. Vassilev,et al.  Targeting the p53–MDM2 interaction to treat cancer , 2004, British Journal of Cancer.

[124]  D. Sze,et al.  Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin , 2005, Cancer Gene Therapy.